Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nitric oxide versus vasodilator and inotropic pharmacologic testing for reversibility of post-capillary pulmonary hypertension in heart transplant candidates
2008-005988-33Phase 3Active
- Sponsor
- CHU de Nantes
- Start
- Nov 2008
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of nitric oxide, furosemide, dobutamine, isosorbide dinitrate and enoximone in pulmonary hypertension due to left heart disease (PH-LHD), sponsored by CHU de Nantes. Primary endpoint: Pulmonary hypertension reversibility threshold. Started Nov 2008; status: active.
02
Drugs
nitric oxidefurosemidedobutamineisosorbide dinitrateenoximone
03
Conditions
pulmonary hypertension due to left heart disease (PH-LHD)
Beyond the preview
Go deeper on 2008-005988-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005988-33.